Unravelling the mechanisms governing the reprogramming of metabolic pathways associated with PEDF treatment in BC cells in the context of glycaemic conditions can open up new avenues for further targeted research and ultimately enhance the development of more effective cancer treatments. The gene discussed is SERPINF1; the disease is cancer.